Kim Vilbour Andersen

Title: Innovations of Kim Vilbour Andersen – A Pioneer in Polypeptide Variants

Introduction

Kim Vilbour Andersen, based in Broenshoej, Denmark, is a remarkable inventor in the field of biotechnology. With an impressive portfolio of 44 patents, he has contributed significantly to advancements in therapeutic treatments related to coagulation-related disorders. His inventions focus on polypeptide variants that have potential applications in medical therapies.

Latest Patents

Among Kim Vilbour Andersen's latest innovations is a patent concerning Factor VII or VIIa polypeptide variants. This invention details novel polypeptide variants of factor VII (FVII) or factor VIIa (FVIIa) that include amino acid substitutions at positions 10 and 32. Moreover, these variants also feature a sugar moiety that is covalently attached to an introduced in vivo N-glycosylation site positioned outside the Gla domain. These advancements provide therapeutic options particularly for the treatment of various coagulation-related disorders such as trauma.

Another noteworthy patent involves Gla domain variants of human Factor VII or human Factor VIIa. This invention comprises 1-15 amino acid modifications relative to the human Factor VII or human Factor VIIa sequence, specifically introducing a hydrophobic amino acid residue through substitution in position 34 or an amino acid substitution in position 36. These variants are designed for therapeutic use in treating intracerebral hemorrhage (ICH) or trauma.

Career Highlights

Throughout his career, Kim Vilbour Andersen has made significant strides while working for reputable organizations in the industry. Notable among these is Maxygen Holdings Ltd., where pioneering research and innovative solutions were at the forefront of their mission. Additionally, he has contributed his expertise to Bayer Healthcare LLC, further expanding his impact within the pharmaceutical sector.

Collaborations

Collaboration has played a vital role in Kim’s inventive journey. He has worked alongside esteemed colleagues like Claus Bornaes and Anders Pedersen, enriching his research endeavors and facilitating the cross-pollination of innovative ideas that lead to meaningful advancements in the field.

Conclusion

Kim Vilbour Andersen stands out as an inventor dedicated to pushing the boundaries of biotechnology through his work on polypeptide variants. His 44 patents demonstrate his commitment to developing therapeutic solutions for critical health issues. With a robust career and valuable collaborations, Andersen continues to inspire the next generation of innovators in the biomedical field.